Senzime AB (publ) (FRA:6YC)

Market Cap	70.67M +9.6%
Revenue (ttm)	9.61M +77.9%
Net Income	-12.70M
EPS	-0.09
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,064
Average Volume	n/a
Open	0.4220
Previous Close	0.4180
Day's Range	0.4020 - 0.4220
52-Week Range	0.3005 - 0.7500
Beta	n/a
RSI	48.12
Earnings Date	Feb 18, 2026

About Senzime AB

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue’s opposition to carrying an alternating electrical current. It also pr...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1999
• Employees: 54
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6YC

Financial Performance

In 2025, Senzime AB's revenue was 104.02 million, an increase of 77.89% compared to the previous year's 58.48 million. Losses were -137.42 million, 15.7% more than in 2024.

Financial numbers in SEK